Early Treatment With Invasive Technique in Cancer Pain Management
NCT05594459 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 76
Last updated 2022-10-26
Summary
Background: high or moderate intensity pain hits more than a half of patients with cancer and is not adequately treated way in 1/3 of this patients. Complexity of cancer pain makes right management difficult and the consequences of an incorrect management are far-reaching in a clinical and social way. A multimodal treatment tailored on the patient, and the evaluation of quality of life correlated to different treatment methodologies, must constitute a decisive element in terms of therapeutic choices.
Over the past 30 years, the World Health Organization (WHO) analgesic step ladder has been used to guide the choices management of cancer-related pain, but in the last years the growth of innovative treatment strategies, led to the need to modulate this rigid yet useful system. Benefits would be obtained with interventional techniques (peripheral neural blockade, neuromodulatory device use, neuro-destructive techniques, and intrathecal drug delivery systems) performed in the initial parts of the treatment cycle (before the third step of the WHO scale), rather than applied according to the WHO scale algorithm. Some authors who adopted this approach, reported reduction in pain duration and less opioid consumption, minimizing the risk of opioid related side effects and an improving the overall quality of life .
The hypothesis is that early application of interventional techniques in oncological patients has an improving effect in the treatment of chronic cancer pain in terms of efficacy and quality of life.
Materials and methods: patients followed by the Cancer Pain Therapy Service of the Cancer National Institute Regina Elena, Rome, with chronic localizable abdominal pain with a value ≥ 7 according to the numeric rating scale (NRS) and a diagnosis of untreatable disease will be randomized into two groups: in the first group patients will be treated with early interventional neuromodulatory techniques, before high opioids dosages. The other group will follow the steps of the WHO scale.
Every patient will receive the European Organization for Research and Treatment of Cancer Quality of life-Core 30 Summary Score (EORTC-QLQ C30) survey to detect quality of life and the Numeric rate scale NRS. They will receive it before the treatment, after invasive procedure, one month later and six months later.
Primary end point will be the difference of the quality of life questionnaire score between the groups; secondary end point will be difference in the NRS values. The statistic analysis will be based on two groups of patients responding to the including criteria. The sample will be made of 76 patients divided in two sub-sample of equal dimension to select and analyze in 18 months. The sample thus defined is consistent for a confidence interval of 80% and for a margin of error of less than 5%.
Conditions
- Cancer Pain
- Opioid Use
Interventions
- PROCEDURE
-
Mini invasive analgesic technique
patients will be treated with early interventional neuromodulatory techniques, before high opioids dosages.
- DRUG
-
high opioids dosages
patients will be treated with high opioids dosages
Sponsors & Collaborators
-
Regina Elena Cancer Institute
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-11-25
- Primary Completion
- 2024-07-25
- Completion
- 2024-12-30
More Related Trials
-
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain
NCT00929188 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Ultra-low Dose Methadone as Adjuvant Analgesic in Cancer Patients With Pain
NCT02687347 ·Status: UNKNOWN ·Phase: PHASE3
-
Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain
NCT00478101 ·Status: COMPLETED ·Phase: PHASE2
-
An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain
NCT00641667 ·Status: COMPLETED ·Phase: PHASE3
-
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
NCT00666211 ·Status: COMPLETED ·Phase: PHASE3
-
Morphine as First Drug for Cancer Pain
NCT01541124 ·Status: COMPLETED ·Phase: NA
-
Usefulness of Acetaminophen Associated With Strong Opioids for Acute Pain in Cancer Patients
NCT04779567 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer
NCT00269737 ·Status: COMPLETED ·Phase: PHASE3
-
Utility of an APP for the Monitoring of Irruptive Oncological Pain
NCT03597737 ·Status: COMPLETED ·Phase: NA
-
A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain
NCT00644787 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Clinical Use and Safety of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer
NCT00269763 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer
NCT01842893 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Efficacy and Safety of Fentanyl Delivered by Adhesive Skin Patch in Out-Patients With Chronic Cancer Pain
NCT00236327 ·Status: TERMINATED ·Phase: PHASE4
-
Methadone Associated With Morphine for Cancer Pain
NCT03324815 ·Status: UNKNOWN ·Phase: NA
-
Study of Opioid Rotation Versus Opioid Escalation in Patients With Moderate to Severe Cancer Pain
NCT02084355 ·Status: UNKNOWN ·Phase: PHASE3
-
A Comparison of the Perception of a Needle Injection Pain Between Cancer Patients Receiving Opioid Therapy Versus Opioid-naive Patients
NCT01704469 ·Status: COMPLETED ·Phase: NA
-
An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Cancer Participants With Inadequately Controlled Pain by Non-Narcotic Analgesics
NCT01060124 ·Status: COMPLETED ·Phase: PHASE4
-
Nasal Fentanyl for Chronic Cancer Pain
NCT01906073 ·Status: WITHDRAWN ·Phase: PHASE3
-
Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With Moderate Cancer Pain
NCT04533243 ·Status: UNKNOWN ·Phase: PHASE3
-
Morphine for the Treatment of Pain in Patients With Breast Cancer
NCT00003000 ·Status: COMPLETED
-
A Study to Evaluate the Safety and Effectiveness of Fentanyl-TTS Compared to Weak Opioids in Patients With Moderate to Severe Chronic Cancer Pain Previously Treated With NSAIDS (Non-steroidal Anti-inflammatory Drugs).
NCT00576017 ·Status: COMPLETED ·Phase: PHASE4
-
Bioavailability and Effectiveness of Transdermally Administered Morphine
NCT00125684 ·Status: COMPLETED ·Phase: PHASE1
-
Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients
NCT03809455 ·Status: WITHDRAWN ·Phase: PHASE2
-
Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration
NCT04243954 ·Status: COMPLETED ·Phase: PHASE2
-
Correlation Between the Analgesic Effect of Fentanyl Transdermal Patches and Nutritional Status in Cancer Pain Patients
NCT06369961 ·Status: COMPLETED